组蛋白去乙酰化调控三阴性乳腺癌细胞增殖影响的研究
|
摘要
[背景和目的]
乳腺癌是女性发病率较高的恶性肿瘤之一,全世界每年大概有1300000的乳腺癌新增病例,其中超过15%的患者是三阴性乳腺癌。三阴性乳腺癌(Triple-Negative Breast Cancer,TNBC)指的是雌激素受体(estrogen receptor,ER),孕激素受体(progesterone receptor,PR)和人表皮生长因子受体2(human epidermal growth factor receptor2,Her-2)均表达缺失的乳腺癌。此类乳腺癌一般组织学分级高、侵袭性强、预后差。对内分泌药物和针对Her-2的靶向治疗无效。相对于其他类型的乳腺癌,TNBC对含紫杉类和蒽环类的新辅助化疗有较高的病理完全缓解率和临床反应率,但是无复发生存率及总体生存率低于非TNBC。易在短期内复发,内脏转移率高于骨转移,脑转移率也较高,死亡风险高。这就使得为TNBC患者寻找一个有效地治疗药物成为一个亟待解决的问题。
近年来,表观遗传学方面的研究逐渐受到人们的关注,表观遗传学是指不涉及DNA序列改变的基因或者蛋白表达的变化,并可以在发育和细胞增殖过程中稳定传递的遗传学。研究发现其与多种疾病、肿瘤的发生发展有关。组蛋白乙酰化修饰是表观遗传学中的重要组成部分,组蛋白乙酰化酶(HAT)和组蛋白去乙酰化酶(HDAC)之间的动态平衡控制着染色质结构和基因表达。两者间的动态平衡失调会导致肿瘤的发生。Ⅰ型HDAC中的HDAC1对肿瘤细胞的增殖起重要的的作用。HDAC抑制剂可通过调节异常增生和(或)凋亡基因的表达抑制肿瘤细胞的生长和存活。研究表明,HDAC抑制剂对多种肿瘤细胞,包括膀胱、卵巢、骨、食管、肺等均表现出良好的抗肿瘤作用。
有研究证实HDAC抑制剂对雌激素受体阳性或阴性的乳腺癌细胞都有抑制作用,动物实验表明其与化疗药联用可增强其疗效,本实验构建HDAC1质粒,转染三阴性乳腺癌细胞(正向干预),另外将HDAC抑制剂作用与三阴性乳腺癌细胞(负向干预),通过观察细胞内周期素CyclinA2、CyclinD1和抑癌基因P21、14-3-3σ蛋白表达的变化探讨HDAC抑制剂对TNBC细胞增殖的影响机制,为临床上研发HDAC抑制剂做为一种新的治疗TNBC患者的分子靶向药物提供一个基础研究参考。
[方法]本研究包括二部分
1、组蛋白去乙酰化酶1对三阴性乳腺癌细胞增殖的影响(正向干预)
1.1通过基因亚克隆(Subcloning)技术构建组蛋白去乙酰化酶1质粒(pcDNA3.1-hdacl)本实验室前期工作已完成；
1.2CaCl2法制备感受态细菌(E.coli);
1.3pcDNA3.1-hdacl质粒转化感受态细菌(E.coli)扩增质粒,进行质粒提纯、酶切鉴定；
1.4pcDNA3.1-hdacl质粒转染三阴性乳腺癌细胞株,用Western印迹法检测质粒蛋白表达：
1.5流式细胞术检测转染质粒前后细胞周期及四种蛋白Cyclin A2、Cyclin D1、P21、14-3-3σ的变化。
1.6用Western印迹法检测四种蛋白Cyclin A2、Cyclin D1、P21、14-3-3σ的变化。
2、组蛋白去乙酰化酶抑制剂对三阴性乳腺癌细胞增殖的影响(负向干预)
2.1倒置显微镜下观察组蛋白去乙酰化酶抑制剂SAHA对三阴性乳腺癌细胞增殖的影响
2.2MTS比色法计算组蛋白去乙酰化酶抑制剂SAHA对三阴性乳腺癌细胞增殖的影响；
2.3流式细胞术检测组蛋白去乙酰化酶抑制剂SAHA对细胞周期和四种蛋白Cyclin A2、Cyclin D1、P21和14-3-3σ的影响。
2.4用Western印迹法检测组蛋白去乙酰化酶抑制剂SAHA对四种蛋白Cyclin A2、Cyclin D1、P21和14-3-3σ的影响变化。
[结果]
1、组蛋白去乙酰化酶1对三阴性乳腺癌细胞增殖的影响(正向干预)
1.1组蛋白去乙酰化酶1质粒(pcDNA3.1-hdac1)的构建与鉴定
亚克隆构建组蛋白去乙酰化酶1质粒(pcDNA3.1-hdac1)成功后,进行质粒提纯、酶切鉴定,证实hdacl DNA片段为1449bp(克隆位点为BamH I/EcoR I);转染三阴性乳腺癌细胞株,Western印迹法检出有HDAC1蛋白表达
1.2组蛋白去乙酰化酶1对三阴性乳腺癌细胞增殖周期的影响
流式细胞术检测显示：未转染HDAC1质粒的三阴性乳腺癌细胞株MDA-MB-468细胞的G1,S期细胞的比例分别为(60.2±0.3)%,(13.7±0.2)%,而转染后的三阴性乳腺癌细胞株MDA-MB-468细胞中代表细胞增殖的S期细胞比例增加(36.1±0.3)%,P<0.05；G1期细胞比例下降(45.7-0.2)%,P<0.05。
1.3组蛋白去乙酰化酶1对三阴性乳腺癌细胞中四种蛋白的影响
流式细胞术检测显示：转染HDAC1后三阴性乳腺癌细胞的Cyclin A2较对照组增加,增幅超过20%,Cyclin D1、P21、14-3-3σ较对照组减少。Western印迹法亦表明转染组较对照组Cyclin A2增加,Cyclin D1、P21、14-3-3σ较对照组减少
2、组蛋白去乙酰化酶抑制剂对三阴性乳腺癌细胞增殖的影响(负向干预)
MTS比色法显示MDA-MB-468细胞在加入组蛋白酶去乙酰化酶抑制剂SAHA24h后出现细胞生长抑制,抑制效应随时间的增加而逐渐增加,并逐渐出现细胞凋亡,72h达高峰,FCM检测显示在加入SAHA48h后MDA-MB-468细胞出现S期细胞比例下降,细胞内CyclinA2蛋白的表达量下降,Cyclin D1、P21、14-3-3σ蛋白的表达量上升,细胞凋亡率上升,与MDA-MB-468对照组比较差异有统计学意义(P＜0.05), Western印迹法显示,MDA-MB-468细胞在加入SAHA48h后Cyclin A2蛋白表达量下降,Cycli0D1、P21、14-3-3σ蛋白的表达量上升。
[结论]
1、组蛋白去乙酰化酶1(HDAC1)基因在三阴性乳腺癌细胞中有表达,其表达对三阴性乳腺癌细胞的增殖有促进作用。
2、SAHA是TNBC细胞增殖的高效抑制剂并促进其凋亡,其抑制作用有一定的时效关系：抑癌基因P21、14-3-3σ和周期数Cyclin A2、cyclinD1参与SAHA对细胞增殖周期的调控。
[Background and Objective]
Breast cancer is one of the higher mortality rates of malignant tumors for woman. There are about1,300,000new cases of breast cancer all over the world. Among these new patients, there are over15%are triple negative breast cancer. Breast cancer, which show estrogen receptor(ER), progesterone receptor (PR) and human epidermal growth factor receptor2(Her-2) all negative, is called tripe negative breast cancer (TNBC). This kind of breast tumor always has higher histologic grade, stronger invasion and poor prognosis. It is invalid to endocrine drugs and targeted therapy drugs for Her-2. Compared to other kinds of breast cancer, patience of TNBC can get higher pathologic complete remission and clinical response rates to the neoadjuvant chemotherapy which contains paclitaxel and anthracycline, but also would get lower recurrence-free and overall survival rates. It has an easier shorten recurrence, a higher rate of brain metastases and internal metastases than bone metastases, and also a higher death rate. So it becomes an urgent problem to find an effective therapeutic drug for TNBC patients.
In recent years, people gradually pay attention to the research on Epigenetics. Epigenetics, which is a branch of genetics and can transfer stably during development and cell proliferation, is not related to DNA sequence alterations of gene or protein expression changes. It is found that epigenetics related to the occurrence and development of many diseases and cancers. Histone acetylation is an important part of epigenetics. The dynamic equilibrium between Histone acetyltransferase (HAT) and histone deacetylase (HDAC) can control the chromatin structure and gene expression. The disorders of their dynamic balance can lead to tumor. HDAC1, type I of HDAC, play an important role on the proliferation of tumor cell. HDAC inhibitors can inhibit the growth and survival of tumor cell through regulating the abnormal proliferation and (or) the expression of apoptosis-related gene. Research shows that HDAC inhibitors have shown a good antitumor effect on a variety of tumor cells including bladder, ovarian, lung, bone, esophageal. Studies have confirmed that HDAC inhibitors can inhibit estrogen receptor positive or negative breast cancer cells. The animal experiment shows that the combination between HDAC inhibitor and chemotherapeutic drugs may enhance the curative effect. Our experiment is to make the construction of HDAC1plasmid and transfer it to the TNBC cells (positive intervention). Meanwhile we put HDAC inhibitor on the other TNBC cells and look for the mechanism by observing the changes of expression on cell cyclin cyclinA2, cyclin D2and tumor suppressor gene P21,14-3-3sigma protein. It can provide a basic study reference for developing HDAC inhibitor as a new molecular targeted drug for TNBC patients.
【Methods】 The study includes two parts
1. Effect of histone deacetylase1(HDAC1) on triple negative breast cancer cell proliferation (Positive intervention)
1.1To construct histone deacetylase1(HDAC1) plasimid (pcDNA3.1-hdac1) by subcloning technology;(our previous work has been completed)
1.2To make competence bacterium (E.coli) by CaCl2method;
1.3To transform pcDNA3.1-hdacl plasimid into competence bacterium (E.coli), harvest large number of pcDNA3.1-hdacl plasimid, purify and check it by the enzyme digestion;
1.4To transfect the TNBC cell with pcDNA3.1-hdacl plasimid, detect the protein expression level with the western bloting;
1.5To examine the change of TNBC cell cycle and the expression of four protein (cylin A2, cylin D2, P21,14-3-3sigma) after transfection of pcDNA3.1-hdacl plasimid by using Flow cytometry (FCM).
1.6To examine the change of the four protein expression cylin A2, cylin D2, P21, and14-3-3sigma by using the western bloting.
2. Effect of histone deacetylase inhibitor on triple negative breast cancer cell proliferation (Negative intervention)
2.1To observe the change of TNBC cell proliferation after being treated by histone deacetylase inhibitor SAHA under inverted microscope.
2.2To calculate the change of TNBC cell cycle after being treated histone deacetylase inhibitor SAHA by MTS method.
2.3To examine the change of TNBC cell cycle and four protein after treatment of histone deacetylase inhibitor SAHA by using Flow cytometry (FCM).
2.4To examine the change of four protein after treatment of histone deacetylase inhibitor SAHA by using western blotting.
【Results】
1. Effect of histone deacetylase1(HDAC1) on triple negative breast cancer cell proliferation (Positive intervention)
1.1Construction and identification of histone deacetylase1(HDAC1) plasimid (pcDNA3.1-hdacl):After successfully constructing of histone deacetylase1(HDAC1) plasimid (pcDNA3.1-hdac1), we confirmed that hdacl DNA fragment is1449bp (cutting position spot is BamH I/EcoR I)by the enzyme digestion; Western bloting showed HDAC1protein expression in TNBC cell lines after transfection of HDAC1plasimid.
1.2Effect of histone deacetylase1(HDAC1) on TNBC MDA-MB-468cell cycle: before transfection of HDAC1plasimid into cells: Flow cytometry(FCM)showed: G1phase cell proportion (60.2±0.3)%, S-phase cell proportion (13.7±0.2)%.after transfection of HDAC1plasimid into cells, Flow cytometry(FCM)showed: G1phase cell proportion dropped(45.7±0.2)%, S-phase cell proportion increased (36.1±0.3)%,; Compared between the two cell lines, P<0.05.
1.3Study of the influence of histone deacetylase1(HDAC1) on four proteins. FCM showed:after transfection of HDAC1plasimid into TNBC cells, the protein CyclinA2increased over20%; the protein CyclinD2、P21、14-3-3σ decreased; compared between transfected and control group, P<0.05. The western blotting also showed the same result.
2. Effect of histone deacetylase inhibitor (HDACi) on TNBC cell proliferation.(Negative intervention)
2.1MTS showed after24h treatment of SAHA, the cell demonstrated growth inhibition and cell apoptosis, the greatest inhibition happened at72h after treatment; FCM showed after adding histone deacetylase inhibitor SAHA on MDA-MB-468cell48h, S-phase cell proportion decreased, the expression of CyclinA2decreased, the expression of Cyclin Dl、P21、14-3-3σ increased, also the cell apoptosis increased. Compared to control group, P<0.05. The western blotting also showed the same result.
【Conclusions】
1. The histone deacetylase1(HDAC1) gene express in TNBC cell line, its expression can promote cancer cell growth;
2. SAHA is an efficient inhibitor for the proliferation of TNBC cells and can promote their cell apoptosis. Its inhibition is related on time. Tumor suppressor gene P21、14-3-3σ and Cyclin A2、cyclinDl participated in the regulation of SAHA on the cell proliferation.
乳腺癌是女性发病率较高的恶性肿瘤之一,全世界每年大概有1300000的乳腺癌新增病例,其中超过15%的患者是三阴性乳腺癌。三阴性乳腺癌(Triple-Negative Breast Cancer,TNBC)指的是雌激素受体(estrogen receptor,ER),孕激素受体(progesterone receptor,PR)和人表皮生长因子受体2(human epidermal growth factor receptor2,Her-2)均表达缺失的乳腺癌。此类乳腺癌一般组织学分级高、侵袭性强、预后差。对内分泌药物和针对Her-2的靶向治疗无效。相对于其他类型的乳腺癌,TNBC对含紫杉类和蒽环类的新辅助化疗有较高的病理完全缓解率和临床反应率,但是无复发生存率及总体生存率低于非TNBC。易在短期内复发,内脏转移率高于骨转移,脑转移率也较高,死亡风险高。这就使得为TNBC患者寻找一个有效地治疗药物成为一个亟待解决的问题。
近年来,表观遗传学方面的研究逐渐受到人们的关注,表观遗传学是指不涉及DNA序列改变的基因或者蛋白表达的变化,并可以在发育和细胞增殖过程中稳定传递的遗传学。研究发现其与多种疾病、肿瘤的发生发展有关。组蛋白乙酰化修饰是表观遗传学中的重要组成部分,组蛋白乙酰化酶(HAT)和组蛋白去乙酰化酶(HDAC)之间的动态平衡控制着染色质结构和基因表达。两者间的动态平衡失调会导致肿瘤的发生。Ⅰ型HDAC中的HDAC1对肿瘤细胞的增殖起重要的的作用。HDAC抑制剂可通过调节异常增生和(或)凋亡基因的表达抑制肿瘤细胞的生长和存活。研究表明,HDAC抑制剂对多种肿瘤细胞,包括膀胱、卵巢、骨、食管、肺等均表现出良好的抗肿瘤作用。
有研究证实HDAC抑制剂对雌激素受体阳性或阴性的乳腺癌细胞都有抑制作用,动物实验表明其与化疗药联用可增强其疗效,本实验构建HDAC1质粒,转染三阴性乳腺癌细胞(正向干预),另外将HDAC抑制剂作用与三阴性乳腺癌细胞(负向干预),通过观察细胞内周期素CyclinA2、CyclinD1和抑癌基因P21、14-3-3σ蛋白表达的变化探讨HDAC抑制剂对TNBC细胞增殖的影响机制,为临床上研发HDAC抑制剂做为一种新的治疗TNBC患者的分子靶向药物提供一个基础研究参考。
[方法]本研究包括二部分
1、组蛋白去乙酰化酶1对三阴性乳腺癌细胞增殖的影响(正向干预)
1.1通过基因亚克隆(Subcloning)技术构建组蛋白去乙酰化酶1质粒(pcDNA3.1-hdacl)本实验室前期工作已完成；
1.2CaCl2法制备感受态细菌(E.coli);
1.3pcDNA3.1-hdacl质粒转化感受态细菌(E.coli)扩增质粒,进行质粒提纯、酶切鉴定；
1.4pcDNA3.1-hdacl质粒转染三阴性乳腺癌细胞株,用Western印迹法检测质粒蛋白表达：
1.5流式细胞术检测转染质粒前后细胞周期及四种蛋白Cyclin A2、Cyclin D1、P21、14-3-3σ的变化。
1.6用Western印迹法检测四种蛋白Cyclin A2、Cyclin D1、P21、14-3-3σ的变化。
2、组蛋白去乙酰化酶抑制剂对三阴性乳腺癌细胞增殖的影响(负向干预)
2.1倒置显微镜下观察组蛋白去乙酰化酶抑制剂SAHA对三阴性乳腺癌细胞增殖的影响
2.2MTS比色法计算组蛋白去乙酰化酶抑制剂SAHA对三阴性乳腺癌细胞增殖的影响；
2.3流式细胞术检测组蛋白去乙酰化酶抑制剂SAHA对细胞周期和四种蛋白Cyclin A2、Cyclin D1、P21和14-3-3σ的影响。
2.4用Western印迹法检测组蛋白去乙酰化酶抑制剂SAHA对四种蛋白Cyclin A2、Cyclin D1、P21和14-3-3σ的影响变化。
[结果]
1、组蛋白去乙酰化酶1对三阴性乳腺癌细胞增殖的影响(正向干预)
1.1组蛋白去乙酰化酶1质粒(pcDNA3.1-hdac1)的构建与鉴定
亚克隆构建组蛋白去乙酰化酶1质粒(pcDNA3.1-hdac1)成功后,进行质粒提纯、酶切鉴定,证实hdacl DNA片段为1449bp(克隆位点为BamH I/EcoR I);转染三阴性乳腺癌细胞株,Western印迹法检出有HDAC1蛋白表达
1.2组蛋白去乙酰化酶1对三阴性乳腺癌细胞增殖周期的影响
流式细胞术检测显示：未转染HDAC1质粒的三阴性乳腺癌细胞株MDA-MB-468细胞的G1,S期细胞的比例分别为(60.2±0.3)%,(13.7±0.2)%,而转染后的三阴性乳腺癌细胞株MDA-MB-468细胞中代表细胞增殖的S期细胞比例增加(36.1±0.3)%,P<0.05；G1期细胞比例下降(45.7-0.2)%,P<0.05。
1.3组蛋白去乙酰化酶1对三阴性乳腺癌细胞中四种蛋白的影响
流式细胞术检测显示：转染HDAC1后三阴性乳腺癌细胞的Cyclin A2较对照组增加,增幅超过20%,Cyclin D1、P21、14-3-3σ较对照组减少。Western印迹法亦表明转染组较对照组Cyclin A2增加,Cyclin D1、P21、14-3-3σ较对照组减少
2、组蛋白去乙酰化酶抑制剂对三阴性乳腺癌细胞增殖的影响(负向干预)
MTS比色法显示MDA-MB-468细胞在加入组蛋白酶去乙酰化酶抑制剂SAHA24h后出现细胞生长抑制,抑制效应随时间的增加而逐渐增加,并逐渐出现细胞凋亡,72h达高峰,FCM检测显示在加入SAHA48h后MDA-MB-468细胞出现S期细胞比例下降,细胞内CyclinA2蛋白的表达量下降,Cyclin D1、P21、14-3-3σ蛋白的表达量上升,细胞凋亡率上升,与MDA-MB-468对照组比较差异有统计学意义(P＜0.05), Western印迹法显示,MDA-MB-468细胞在加入SAHA48h后Cyclin A2蛋白表达量下降,Cycli0D1、P21、14-3-3σ蛋白的表达量上升。
[结论]
1、组蛋白去乙酰化酶1(HDAC1)基因在三阴性乳腺癌细胞中有表达,其表达对三阴性乳腺癌细胞的增殖有促进作用。
2、SAHA是TNBC细胞增殖的高效抑制剂并促进其凋亡,其抑制作用有一定的时效关系：抑癌基因P21、14-3-3σ和周期数Cyclin A2、cyclinD1参与SAHA对细胞增殖周期的调控。
[Background and Objective]
Breast cancer is one of the higher mortality rates of malignant tumors for woman. There are about1,300,000new cases of breast cancer all over the world. Among these new patients, there are over15%are triple negative breast cancer. Breast cancer, which show estrogen receptor(ER), progesterone receptor (PR) and human epidermal growth factor receptor2(Her-2) all negative, is called tripe negative breast cancer (TNBC). This kind of breast tumor always has higher histologic grade, stronger invasion and poor prognosis. It is invalid to endocrine drugs and targeted therapy drugs for Her-2. Compared to other kinds of breast cancer, patience of TNBC can get higher pathologic complete remission and clinical response rates to the neoadjuvant chemotherapy which contains paclitaxel and anthracycline, but also would get lower recurrence-free and overall survival rates. It has an easier shorten recurrence, a higher rate of brain metastases and internal metastases than bone metastases, and also a higher death rate. So it becomes an urgent problem to find an effective therapeutic drug for TNBC patients.
In recent years, people gradually pay attention to the research on Epigenetics. Epigenetics, which is a branch of genetics and can transfer stably during development and cell proliferation, is not related to DNA sequence alterations of gene or protein expression changes. It is found that epigenetics related to the occurrence and development of many diseases and cancers. Histone acetylation is an important part of epigenetics. The dynamic equilibrium between Histone acetyltransferase (HAT) and histone deacetylase (HDAC) can control the chromatin structure and gene expression. The disorders of their dynamic balance can lead to tumor. HDAC1, type I of HDAC, play an important role on the proliferation of tumor cell. HDAC inhibitors can inhibit the growth and survival of tumor cell through regulating the abnormal proliferation and (or) the expression of apoptosis-related gene. Research shows that HDAC inhibitors have shown a good antitumor effect on a variety of tumor cells including bladder, ovarian, lung, bone, esophageal. Studies have confirmed that HDAC inhibitors can inhibit estrogen receptor positive or negative breast cancer cells. The animal experiment shows that the combination between HDAC inhibitor and chemotherapeutic drugs may enhance the curative effect. Our experiment is to make the construction of HDAC1plasmid and transfer it to the TNBC cells (positive intervention). Meanwhile we put HDAC inhibitor on the other TNBC cells and look for the mechanism by observing the changes of expression on cell cyclin cyclinA2, cyclin D2and tumor suppressor gene P21,14-3-3sigma protein. It can provide a basic study reference for developing HDAC inhibitor as a new molecular targeted drug for TNBC patients.
【Methods】 The study includes two parts
1. Effect of histone deacetylase1(HDAC1) on triple negative breast cancer cell proliferation (Positive intervention)
1.1To construct histone deacetylase1(HDAC1) plasimid (pcDNA3.1-hdac1) by subcloning technology;(our previous work has been completed)
1.2To make competence bacterium (E.coli) by CaCl2method;
1.3To transform pcDNA3.1-hdacl plasimid into competence bacterium (E.coli), harvest large number of pcDNA3.1-hdacl plasimid, purify and check it by the enzyme digestion;
1.4To transfect the TNBC cell with pcDNA3.1-hdacl plasimid, detect the protein expression level with the western bloting;
1.5To examine the change of TNBC cell cycle and the expression of four protein (cylin A2, cylin D2, P21,14-3-3sigma) after transfection of pcDNA3.1-hdacl plasimid by using Flow cytometry (FCM).
1.6To examine the change of the four protein expression cylin A2, cylin D2, P21, and14-3-3sigma by using the western bloting.
2. Effect of histone deacetylase inhibitor on triple negative breast cancer cell proliferation (Negative intervention)
2.1To observe the change of TNBC cell proliferation after being treated by histone deacetylase inhibitor SAHA under inverted microscope.
2.2To calculate the change of TNBC cell cycle after being treated histone deacetylase inhibitor SAHA by MTS method.
2.3To examine the change of TNBC cell cycle and four protein after treatment of histone deacetylase inhibitor SAHA by using Flow cytometry (FCM).
2.4To examine the change of four protein after treatment of histone deacetylase inhibitor SAHA by using western blotting.
【Results】
1. Effect of histone deacetylase1(HDAC1) on triple negative breast cancer cell proliferation (Positive intervention)
1.1Construction and identification of histone deacetylase1(HDAC1) plasimid (pcDNA3.1-hdacl):After successfully constructing of histone deacetylase1(HDAC1) plasimid (pcDNA3.1-hdac1), we confirmed that hdacl DNA fragment is1449bp (cutting position spot is BamH I/EcoR I)by the enzyme digestion; Western bloting showed HDAC1protein expression in TNBC cell lines after transfection of HDAC1plasimid.
1.2Effect of histone deacetylase1(HDAC1) on TNBC MDA-MB-468cell cycle: before transfection of HDAC1plasimid into cells: Flow cytometry(FCM)showed: G1phase cell proportion (60.2±0.3)%, S-phase cell proportion (13.7±0.2)%.after transfection of HDAC1plasimid into cells, Flow cytometry(FCM)showed: G1phase cell proportion dropped(45.7±0.2)%, S-phase cell proportion increased (36.1±0.3)%,; Compared between the two cell lines, P<0.05.
1.3Study of the influence of histone deacetylase1(HDAC1) on four proteins. FCM showed:after transfection of HDAC1plasimid into TNBC cells, the protein CyclinA2increased over20%; the protein CyclinD2、P21、14-3-3σ decreased; compared between transfected and control group, P<0.05. The western blotting also showed the same result.
2. Effect of histone deacetylase inhibitor (HDACi) on TNBC cell proliferation.(Negative intervention)
2.1MTS showed after24h treatment of SAHA, the cell demonstrated growth inhibition and cell apoptosis, the greatest inhibition happened at72h after treatment; FCM showed after adding histone deacetylase inhibitor SAHA on MDA-MB-468cell48h, S-phase cell proportion decreased, the expression of CyclinA2decreased, the expression of Cyclin Dl、P21、14-3-3σ increased, also the cell apoptosis increased. Compared to control group, P<0.05. The western blotting also showed the same result.
【Conclusions】
1. The histone deacetylase1(HDAC1) gene express in TNBC cell line, its expression can promote cancer cell growth;
2. SAHA is an efficient inhibitor for the proliferation of TNBC cells and can promote their cell apoptosis. Its inhibition is related on time. Tumor suppressor gene P21、14-3-3σ and Cyclin A2、cyclinDl participated in the regulation of SAHA on the cell proliferation.
引文
1. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [J]. Cancer,2007,109(1):25-32.
2. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed african-american and caucasian patients:a single-institution compilation compared with the national cancer institute's surveillance, epidemiology, and end results database [J]. Cancer,2007,110(4):876-884.
3. Ayca Gucalp, Tiffany A. Traina. Triple-Negative Breast Cancer: Adjuvant Therapeutic Options. [J]. Chemotherapy Research and Practice,2011, doi:10.1155/2011/696208.
4. Lisa A. Carey. Directed Therapy of Subtypes of Triple-Negative Breast Cancer. [J]. The Oncologist,2011,16 (1):71-78.
5. HAYASHI A, HORIUCHI A, KIKUCHI N, et al. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin [J]. Int J Cancer,2010,127(6):1332-1346.
6. 崔世义,孙伟,陈旭伟。HDAC1蛋白在乳腺癌中的表达及临床意义及与ER、PR的关系[J].现代生物医学进展,2011,11(3)：541-545.
7. Smith KT, Workman JL. Histone deacetylase inhibitors:anticancer compounds [J]. Int Biochen Biol Cell Biol,2009,41(1):21-25.
8. 陈竺,主编.医学遗传学(2005)[M].北京：人民卫生出版社,2005：324-35.
9. SILVIA S, KATRIN Z, SIMONE M, et al. Role for Histone Deacetylase 1 in Human Tuman Cell Proliferation [J]. Mol Cell Biol,2007,27(13):4784-4795
10. Smith KT, Workman JL. Histone deacetylase inhibitors:anticancer compounds [J]. Int J Biochem Cell Biol,2009,41 (1):21-25
11. NAKAGAWA M, ODA Y, EGHCHI T, et al. Expression profile of class I histone deacetylases in human cancer tissues[J]. Oncol Rep,2007,18(4):769-774.
12. OZAWA A, TANJI N, KIKUGAWA T, et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor [J].BJU Int,2009,105(18):1181-1186.
13. 张建中,吕怀盛,景丽,等.食管癌组织中P21cipl/WAF、P53表达及HPV-16感染的意 义[J].实用癌症杂志,2004,19(5)：488-490.
14. Sun Y. Li JY, He JS, et al. Tissue micorarry analysis of multiple gene expression in intestinalm otaplasia, dysplasca and carcinoma of the stomach [J]. H-istopathology,2005, 46(5):505-514.
15. SMPSON PT, GALE T, REIS FLHO JS, et al. Distribution and significance of 14-3-3 σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue[J]. J Pathol, 2004,202(3):274-285.
16. YANG H, WEN YY, ZHAO R Y, et al. DNA damage-induced protein 14-3-3 σ inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer[J]. Cancer Res,2006, 66(4):3097-3105.
17. 马劫,徐世荣,贾晋松,等。细胞周期蛋白A在成人急性白血病中的表达及意义[J].中华医学杂志,2003,83(7)：556-560.
18. Haferlach T, Bacher U, Haferlach C, et al. Insight into the molecular pathogenesis of myeloid maligancies[J]. Curr Opin Hemato,2007,14(2):90-97.
19. Corey SJ, M inden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases [J]. NatRev Cancer,2007(2):118-129.
20. Wang X, Zou S. The relationship of Cyclin D1 and estrogen receptor expression in the process of proliferation and metastasis in breast neoplasm [J]. Journal of Tongji Medical University,20021(3):231-232.
[1]Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors [J]. Proc Natl Acad Sci USA, 2005,102(10):3697-3702.
[2]聂建云,刘馨,金从国,等。组蛋白去乙酰化酶抑制剂对乳腺癌细胞株MCF-7增殖周期的影响[J].中国综合临床,2009,25(12)：1238-1240.
[3]Gregoire S, Xiao L, Nie J, et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2[J]. Mol Cell Biol,2007,27(4):1280-1295.
[4]聂建云,陈杨萍,黄云超。组蛋白去乙酰化酶抑制剂联合化疗对乳腺癌细胞增殖影响的动物实验研究[J].中国肿瘤临床,2011,38(4)：189-192.
[5]Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors [J]. Proc Natl Acad Sci USA,2005,102(10):3697-3702.
[6]何向明,刘琳.组蛋白去乙酰化酶及其抑制剂与结直肠癌的关系[J].临床肿瘤学杂志,2009,14(3)：270-273.
[7]Brodska B, Otevrelova P, Holoubek A. Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.[J] Mol Cell Biochem,2011,350(1-2):71-80.
[8]Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid(SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.[J] Cancer,2011, Mar 16. doi:10.1002/cncr.26073.
[9]Tzivion G, Gupta V S, Kaplun L, et al.14-3-3 σ proteins as potential oncogenes [J]. Sem in Cancer Biol,20016 (3):20-213.
[10]Tian H, Faje A T, Lee SL, et al. Radiation-induced phosphorylation of Chkl at S345 is associated with p53-dependent cell cycle arrest pathways [J]. Neoplasia,2004(2):264-269.
[11]Esteller M. DNA methylation and cancer therapy: new developments and expectations [J]. Curr Opin Oncol,20017(1):55-60.
[12]李作生,李保庆.p21和p27基因多态性与肿瘤的相关[J].国际遗传学杂志,2006,29(4)： 3172320.
[13]Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat SAHA) profoundly inhibits the growth of human pancreatic cancer cells[J]. Int J Cancer,2007,121(3):656-665.
[14]马劫,徐世荣,贾晋松,等.细胞周期蛋白A在成人急性白血病中的表达及意义[J].中华医学杂志,2003,83(7)：556—560.
[15]Haferlach T, Bacher U, Haferlach C, et al. Insight into the molecular pathogenesis of myeloid malignancies [J]. Curr Opin Hemato,2007,14 (2):90-97.
[16]Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes:the complexity of stem-cell diseases [J]. NatRev Cancer,2007,7 (2):118-129.
[17]Aaltonen K, Ahlin C, Amini RM, et al. Reliability of cyclinA assessment on tissue microarrays in breast cancer compared to conventional histological slides[J]. British Journal of Cancer,2006,94 (11):1697-1702.
[18]吉爱军,唐金海.乳腺癌术后患者CyclinA1、A2、D1、El表达及其临床意义[J].南京医科大学学报(自然科学版),2010,30(9)：1290—1292。
[19]Luong QT, O'Kelly J, Brannstein GD, et al. Antitumoractivity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo[J]. Clin Cancer Res,2006,12(18): 5570-5577.
[20]Arnold NB, Arkufl N, Gunn J, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer [J]. Clin Cancer Res,2007,13(1):18-26.
[1]沈镇宙,邵志敏.乳腺肿瘤学[M].上海：上海科技出版社2005：1-2.
[2]Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors [J]. Nature,2000,406 (6797):747-752.
[3]Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor (PR)-negative, and HER-2 negative invasive breast cancer, the so-called triple-negative phenotype:A population-based study from the California Cancer Registry[J]. Cancer,2007,109 (9):1721-1728.
[4]关印,徐冰河.三阴性乳腺癌的临床病理特征及预后分析[J].中华肿瘤杂志,2008,30(3)：196-199.
[5]Dent R, Trudeau M, Pritchard KI, et al. Race, breast cancer; Clinical features and patterns of recurrence[J]. Clin Cancer Res,2007,13 (15):4429-4434.
[6]Hatty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer [J]. J Clin Oncol,2006, 24(36):5652-5657.
[7]赵晓辉,郝春芳,王忱,等。三阴性乳腺癌的临床病理学特征及预后分析[OL]。中华乳腺病杂志,2009,3(6)590-599.
[8]Rakha EA, EI-Sayed ME, Green AR, et al. Prognostic Markers in Triple-Negative Breast Cancer[J]. Cancer,2007,109(1):25-32.
[9]Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol,2008, (26):1275-1281.
[10]Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse [J]. J Clin Oncol,2008, (26):1275-1281.
[11]Koshy N, Quispe D, Shi R,et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients [J]. Breast,2010 19 (3):246-8.
[12]Garber JE, Richardson A, Harris LN, et al. Neo-anjuvant cisplatin(CDPP) in " triple-negative " breast cancer(BC). Program and abstracts of the 29th Annual San Antonio Breast Cancer Symposium. December 14-17,2006; Sam Antonio, Texas, Abstract 3074.
[13]Haffty BG, Yang Q, Resiss M, et al. Local-regional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. Proc Am Soc Clin Oncol, 2006,24:594(Abstr).
[14]张保宁,张慧明.三阴性乳腺癌研究进展：第31届圣·安东尼奥乳腺癌研讨会报道[OL].中华乳腺病杂志,2009,3(1)：5-8.
[15]Faimer H, MC Cabe N, Lord CJ, et al.Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy [J]. Nature 2005, (434):917-921.
[16]Futoshi Akiyama. Triple negative breast cancer:clinicopathological characteristic and treatment strategies[J]. Breast Cancer,2009 (16):252-253.
[17]何向明,刘琳.组蛋白去乙酰化酶及其抑制剂与结直肠癌的关系[J].临床肿瘤学杂志,2009,14(3)：270-273.
[18]程焕臣,马军.表观遗传修饰与肿瘤[J].内科理论与实践,2009,4(1)：72-75.
[19]Gao L, Cueto MA, Asselbergs F, et al.Cloning and functional characterization of HDAC1:a novel member of the human histone deacetylase famil y[J]. J Biol,2001,(3):114-120.
[20]Marks PA, Richon VM, Miller T, et al. Histone deacetylase inhibitors[J]. Adv Cancer Res, 2004,(91):137-168.
[21]Zheng L, Annab LA, Afshari CA, et al. BRCA1 mediates ligand-indepent transcri-ptional repression of the estrogen receptor [J]. Proc Natl Acad Sci USA,2001,98(17):9587.
[22]Pasqualini J R, Mercat P, Giambiagi N. Histone acetylatin decreased by estradiol in the MCF-7 human mammary Cancer cell line [J]. Breast cancer RES Treat,1989,14(l):101.
[23]Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stess [J]. Mutat Res,2000,462(2-3):179-188.
[24]Chung Y L, Lee M Y, Wang A J, et al. A therapeutic strategy uses histone deacetylade inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis [J]. Mol Ther,2003,(8):707-717.
[25]Whetstine JR, Ceron J, Ladd B, et al. Regulation of tissue-specific and extracellular matrixrelated genes by a class 1 histone deacetylase[J]. Mol Cell,2005,(18):483-490.
[26]Sawa H, Murakami H, Ohshima Y, et al.Histone deacetylase inhibitors such as sodium butyrate and trichostatin a inhibit vascular endothelial growth factor(VEGF) secretion from human ghoblastoma cells[J]. Brain Tumor Pathol,2002, (19):77-81.
[27]Simooka H, Oyama T, Sano T, et al. Immunohistochemical analysis of 14-3-3sigma and related proteins in hyperplastic and neplastic breast lesions, with particular reference to early carcinogenesis [J]. Lung Cancer,2005,47(2):225-233.
[28]Tian H, Faje A T, Lee SL, et al. Radiation-induced phosphorylation of Chkl at S345 is associated with p53-dependent cell cycle arrest pathways[J]. Neoplasia,2002,4(2):264-269.
[29]易欣,赵名,张旭辉,等。组蛋白去乙酰化酶抑制剂FK228通过阻断Hsp90功能杀伤乳腺癌MCF-7细胞[J].中国癌症杂志,2007,17(5)：349-353.
[30]聂建云,刘馨,金从国,等。HDAC1对乳腺癌细胞MDA-MB-435s增殖的研究[J].山东医药,2009,49(32)：20-22.
[31]黄程辉,曹培国,谢兆霞。MCF-7/Adr细胞mdr-1基因启动子甲基化和组蛋白乙酰化状态与多药耐药的关系[J].中南大学学报,2009,34(5)：0369-0374.
[32]Lehmann-Che J, Andre F, Desmedt C, et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of P53 mutant breast cancers[J]. Oncologist, 2010,15(3):246-252.
[33]Bouwan P, Aly A, Escandell JM, et al.53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers [J]. Nat Struct Mol Biol, 2010,17(6):688-695.
[34]Mutze K, Langer R, Becker K, et al. Histone deacetylase (HDAC)1 and 2 expression and chemotherapy in gastric cancer[J]. Ann Surg Oncol,2010,17(12)3336-3343.
[35]粟厚仪,庄广伦。细胞周期调节基因P21与肿瘤关系的研究进展[J].中国肿瘤,1999,8(5)：222-224.
[36]Hwang JJ, Kim YS, Kim MJ, et al. A novel histone deacetylase inhibitor, CG0066, induces cell death through both extrinsic and intrinsic apoptotic pathways[J]. Anticancer Drugs, 2009,20(9)815-821.
[37]Su CH, Zhao R, Velazquez-Torres G, et al. Nuclear export regualtion of Copl by 14-3-3 σ in response to DNA demage[J]. Mol Cancer,2010, sep15,9:243.
[38]Lodyqin D, Hermeking H. Epigenetic Silencing of 14-3-3 sigma in Cancer [J].Semin Cancer Biol,2006,16(3):214-224.
2. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed african-american and caucasian patients:a single-institution compilation compared with the national cancer institute's surveillance, epidemiology, and end results database [J]. Cancer,2007,110(4):876-884.
3. Ayca Gucalp, Tiffany A. Traina. Triple-Negative Breast Cancer: Adjuvant Therapeutic Options. [J]. Chemotherapy Research and Practice,2011, doi:10.1155/2011/696208.
4. Lisa A. Carey. Directed Therapy of Subtypes of Triple-Negative Breast Cancer. [J]. The Oncologist,2011,16 (1):71-78.
5. HAYASHI A, HORIUCHI A, KIKUCHI N, et al. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin [J]. Int J Cancer,2010,127(6):1332-1346.
6. 崔世义,孙伟,陈旭伟。HDAC1蛋白在乳腺癌中的表达及临床意义及与ER、PR的关系[J].现代生物医学进展,2011,11(3)：541-545.
7. Smith KT, Workman JL. Histone deacetylase inhibitors:anticancer compounds [J]. Int Biochen Biol Cell Biol,2009,41(1):21-25.
8. 陈竺,主编.医学遗传学(2005)[M].北京：人民卫生出版社,2005：324-35.
9. SILVIA S, KATRIN Z, SIMONE M, et al. Role for Histone Deacetylase 1 in Human Tuman Cell Proliferation [J]. Mol Cell Biol,2007,27(13):4784-4795
10. Smith KT, Workman JL. Histone deacetylase inhibitors:anticancer compounds [J]. Int J Biochem Cell Biol,2009,41 (1):21-25
11. NAKAGAWA M, ODA Y, EGHCHI T, et al. Expression profile of class I histone deacetylases in human cancer tissues[J]. Oncol Rep,2007,18(4):769-774.
12. OZAWA A, TANJI N, KIKUGAWA T, et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor [J].BJU Int,2009,105(18):1181-1186.
13. 张建中,吕怀盛,景丽,等.食管癌组织中P21cipl/WAF、P53表达及HPV-16感染的意 义[J].实用癌症杂志,2004,19(5)：488-490.
14. Sun Y. Li JY, He JS, et al. Tissue micorarry analysis of multiple gene expression in intestinalm otaplasia, dysplasca and carcinoma of the stomach [J]. H-istopathology,2005, 46(5):505-514.
15. SMPSON PT, GALE T, REIS FLHO JS, et al. Distribution and significance of 14-3-3 σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue[J]. J Pathol, 2004,202(3):274-285.
16. YANG H, WEN YY, ZHAO R Y, et al. DNA damage-induced protein 14-3-3 σ inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer[J]. Cancer Res,2006, 66(4):3097-3105.
17. 马劫,徐世荣,贾晋松,等。细胞周期蛋白A在成人急性白血病中的表达及意义[J].中华医学杂志,2003,83(7)：556-560.
18. Haferlach T, Bacher U, Haferlach C, et al. Insight into the molecular pathogenesis of myeloid maligancies[J]. Curr Opin Hemato,2007,14(2):90-97.
19. Corey SJ, M inden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases [J]. NatRev Cancer,2007(2):118-129.
20. Wang X, Zou S. The relationship of Cyclin D1 and estrogen receptor expression in the process of proliferation and metastasis in breast neoplasm [J]. Journal of Tongji Medical University,20021(3):231-232.
[1]Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors [J]. Proc Natl Acad Sci USA, 2005,102(10):3697-3702.
[2]聂建云,刘馨,金从国,等。组蛋白去乙酰化酶抑制剂对乳腺癌细胞株MCF-7增殖周期的影响[J].中国综合临床,2009,25(12)：1238-1240.
[3]Gregoire S, Xiao L, Nie J, et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2[J]. Mol Cell Biol,2007,27(4):1280-1295.
[4]聂建云,陈杨萍,黄云超。组蛋白去乙酰化酶抑制剂联合化疗对乳腺癌细胞增殖影响的动物实验研究[J].中国肿瘤临床,2011,38(4)：189-192.
[5]Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors [J]. Proc Natl Acad Sci USA,2005,102(10):3697-3702.
[6]何向明,刘琳.组蛋白去乙酰化酶及其抑制剂与结直肠癌的关系[J].临床肿瘤学杂志,2009,14(3)：270-273.
[7]Brodska B, Otevrelova P, Holoubek A. Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.[J] Mol Cell Biochem,2011,350(1-2):71-80.
[8]Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid(SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.[J] Cancer,2011, Mar 16. doi:10.1002/cncr.26073.
[9]Tzivion G, Gupta V S, Kaplun L, et al.14-3-3 σ proteins as potential oncogenes [J]. Sem in Cancer Biol,20016 (3):20-213.
[10]Tian H, Faje A T, Lee SL, et al. Radiation-induced phosphorylation of Chkl at S345 is associated with p53-dependent cell cycle arrest pathways [J]. Neoplasia,2004(2):264-269.
[11]Esteller M. DNA methylation and cancer therapy: new developments and expectations [J]. Curr Opin Oncol,20017(1):55-60.
[12]李作生,李保庆.p21和p27基因多态性与肿瘤的相关[J].国际遗传学杂志,2006,29(4)： 3172320.
[13]Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat SAHA) profoundly inhibits the growth of human pancreatic cancer cells[J]. Int J Cancer,2007,121(3):656-665.
[14]马劫,徐世荣,贾晋松,等.细胞周期蛋白A在成人急性白血病中的表达及意义[J].中华医学杂志,2003,83(7)：556—560.
[15]Haferlach T, Bacher U, Haferlach C, et al. Insight into the molecular pathogenesis of myeloid malignancies [J]. Curr Opin Hemato,2007,14 (2):90-97.
[16]Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes:the complexity of stem-cell diseases [J]. NatRev Cancer,2007,7 (2):118-129.
[17]Aaltonen K, Ahlin C, Amini RM, et al. Reliability of cyclinA assessment on tissue microarrays in breast cancer compared to conventional histological slides[J]. British Journal of Cancer,2006,94 (11):1697-1702.
[18]吉爱军,唐金海.乳腺癌术后患者CyclinA1、A2、D1、El表达及其临床意义[J].南京医科大学学报(自然科学版),2010,30(9)：1290—1292。
[19]Luong QT, O'Kelly J, Brannstein GD, et al. Antitumoractivity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo[J]. Clin Cancer Res,2006,12(18): 5570-5577.
[20]Arnold NB, Arkufl N, Gunn J, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer [J]. Clin Cancer Res,2007,13(1):18-26.
[1]沈镇宙,邵志敏.乳腺肿瘤学[M].上海：上海科技出版社2005：1-2.
[2]Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors [J]. Nature,2000,406 (6797):747-752.
[3]Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor (PR)-negative, and HER-2 negative invasive breast cancer, the so-called triple-negative phenotype:A population-based study from the California Cancer Registry[J]. Cancer,2007,109 (9):1721-1728.
[4]关印,徐冰河.三阴性乳腺癌的临床病理特征及预后分析[J].中华肿瘤杂志,2008,30(3)：196-199.
[5]Dent R, Trudeau M, Pritchard KI, et al. Race, breast cancer; Clinical features and patterns of recurrence[J]. Clin Cancer Res,2007,13 (15):4429-4434.
[6]Hatty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer [J]. J Clin Oncol,2006, 24(36):5652-5657.
[7]赵晓辉,郝春芳,王忱,等。三阴性乳腺癌的临床病理学特征及预后分析[OL]。中华乳腺病杂志,2009,3(6)590-599.
[8]Rakha EA, EI-Sayed ME, Green AR, et al. Prognostic Markers in Triple-Negative Breast Cancer[J]. Cancer,2007,109(1):25-32.
[9]Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol,2008, (26):1275-1281.
[10]Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse [J]. J Clin Oncol,2008, (26):1275-1281.
[11]Koshy N, Quispe D, Shi R,et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients [J]. Breast,2010 19 (3):246-8.
[12]Garber JE, Richardson A, Harris LN, et al. Neo-anjuvant cisplatin(CDPP) in " triple-negative " breast cancer(BC). Program and abstracts of the 29th Annual San Antonio Breast Cancer Symposium. December 14-17,2006; Sam Antonio, Texas, Abstract 3074.
[13]Haffty BG, Yang Q, Resiss M, et al. Local-regional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. Proc Am Soc Clin Oncol, 2006,24:594(Abstr).
[14]张保宁,张慧明.三阴性乳腺癌研究进展：第31届圣·安东尼奥乳腺癌研讨会报道[OL].中华乳腺病杂志,2009,3(1)：5-8.
[15]Faimer H, MC Cabe N, Lord CJ, et al.Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy [J]. Nature 2005, (434):917-921.
[16]Futoshi Akiyama. Triple negative breast cancer:clinicopathological characteristic and treatment strategies[J]. Breast Cancer,2009 (16):252-253.
[17]何向明,刘琳.组蛋白去乙酰化酶及其抑制剂与结直肠癌的关系[J].临床肿瘤学杂志,2009,14(3)：270-273.
[18]程焕臣,马军.表观遗传修饰与肿瘤[J].内科理论与实践,2009,4(1)：72-75.
[19]Gao L, Cueto MA, Asselbergs F, et al.Cloning and functional characterization of HDAC1:a novel member of the human histone deacetylase famil y[J]. J Biol,2001,(3):114-120.
[20]Marks PA, Richon VM, Miller T, et al. Histone deacetylase inhibitors[J]. Adv Cancer Res, 2004,(91):137-168.
[21]Zheng L, Annab LA, Afshari CA, et al. BRCA1 mediates ligand-indepent transcri-ptional repression of the estrogen receptor [J]. Proc Natl Acad Sci USA,2001,98(17):9587.
[22]Pasqualini J R, Mercat P, Giambiagi N. Histone acetylatin decreased by estradiol in the MCF-7 human mammary Cancer cell line [J]. Breast cancer RES Treat,1989,14(l):101.
[23]Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stess [J]. Mutat Res,2000,462(2-3):179-188.
[24]Chung Y L, Lee M Y, Wang A J, et al. A therapeutic strategy uses histone deacetylade inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis [J]. Mol Ther,2003,(8):707-717.
[25]Whetstine JR, Ceron J, Ladd B, et al. Regulation of tissue-specific and extracellular matrixrelated genes by a class 1 histone deacetylase[J]. Mol Cell,2005,(18):483-490.
[26]Sawa H, Murakami H, Ohshima Y, et al.Histone deacetylase inhibitors such as sodium butyrate and trichostatin a inhibit vascular endothelial growth factor(VEGF) secretion from human ghoblastoma cells[J]. Brain Tumor Pathol,2002, (19):77-81.
[27]Simooka H, Oyama T, Sano T, et al. Immunohistochemical analysis of 14-3-3sigma and related proteins in hyperplastic and neplastic breast lesions, with particular reference to early carcinogenesis [J]. Lung Cancer,2005,47(2):225-233.
[28]Tian H, Faje A T, Lee SL, et al. Radiation-induced phosphorylation of Chkl at S345 is associated with p53-dependent cell cycle arrest pathways[J]. Neoplasia,2002,4(2):264-269.
[29]易欣,赵名,张旭辉,等。组蛋白去乙酰化酶抑制剂FK228通过阻断Hsp90功能杀伤乳腺癌MCF-7细胞[J].中国癌症杂志,2007,17(5)：349-353.
[30]聂建云,刘馨,金从国,等。HDAC1对乳腺癌细胞MDA-MB-435s增殖的研究[J].山东医药,2009,49(32)：20-22.
[31]黄程辉,曹培国,谢兆霞。MCF-7/Adr细胞mdr-1基因启动子甲基化和组蛋白乙酰化状态与多药耐药的关系[J].中南大学学报,2009,34(5)：0369-0374.
[32]Lehmann-Che J, Andre F, Desmedt C, et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of P53 mutant breast cancers[J]. Oncologist, 2010,15(3):246-252.
[33]Bouwan P, Aly A, Escandell JM, et al.53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers [J]. Nat Struct Mol Biol, 2010,17(6):688-695.
[34]Mutze K, Langer R, Becker K, et al. Histone deacetylase (HDAC)1 and 2 expression and chemotherapy in gastric cancer[J]. Ann Surg Oncol,2010,17(12)3336-3343.
[35]粟厚仪,庄广伦。细胞周期调节基因P21与肿瘤关系的研究进展[J].中国肿瘤,1999,8(5)：222-224.
[36]Hwang JJ, Kim YS, Kim MJ, et al. A novel histone deacetylase inhibitor, CG0066, induces cell death through both extrinsic and intrinsic apoptotic pathways[J]. Anticancer Drugs, 2009,20(9)815-821.
[37]Su CH, Zhao R, Velazquez-Torres G, et al. Nuclear export regualtion of Copl by 14-3-3 σ in response to DNA demage[J]. Mol Cancer,2010, sep15,9:243.
[38]Lodyqin D, Hermeking H. Epigenetic Silencing of 14-3-3 sigma in Cancer [J].Semin Cancer Biol,2006,16(3):214-224.